Total U.S. pharmaceutical and biotech revenues for products 5 years after launch from 2007 to 2017 (in billion U.S. dollars)

Total U.S. pharma and biotech product sales 5 years after launch 2007-2017 This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.
Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Show more
Loading statistic...
Revenue in billion U.S. dollars
20074.3
20085.6
20095.4
201012.5
201111.9
2012*13.9
201312.3
201419.8
201523.7
201611
2017**31.6
Revenue in billion U.S. dollars
20074.3
20085.6
20095.4
201012.5
201111.9
2012*13.9
201312.3
201419.8
201523.7
201611
2017**31.6
Download Settings Share
Chart type
Datalabels
Share on Social Media
HTML code to embed chart as PNG (FAQ)
Download started
Please be patient - this may take a moment
Description Source More information
This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.
Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Show more
Release date
December 2017
Region
United States
Survey time period
as of November 2017
Supplementary notes
* Values until 2012 were assembled from previous editions of the report.
** Potential total for 2017.

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Basic Account

Get to know the platform

You only have access to basic statistics.

Register for free

Premium Account

Your perfect start with Statista

  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account

Full access

Corporate solution including all features.

Send request

* All products require an annual contract.
   Prices do not include sales tax
   (New York residents only).
Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Biotech industry

All Information
in one Presentation

Biotech industry

Everything On "Biotech industry" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Biotech industry"

  • Overview U.S. and Europe
The most important statistics
  • Global companies
  • U.S. companies
  • Top U.S. regions
The most important statistics
  • Products/R&D
  • Biotech in agriculture
Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

News